{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:58:15Z","timestamp":1791568695146,"version":"4.3.4"},"reference-count":279,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s11523-022-00900-2","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T03:28:47Z","timestamp":1659151727000},"page":"407-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP"],"prefix":"10.1007","volume":"17","author":[{"given":"Fat\u00e9m\u00e9h","family":"Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bazille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Levallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Maille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannick","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bergot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-0581","authenticated-orcid":false,"given":"Gu\u00e9na\u00eblle","family":"Levallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"issue":"14","key":"900_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3978\/j.issn.2225-319X.2012.11.04","volume":"1","author":"BM Robinson","year":"2021","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2021;1(14):491\u20137. https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2012.11.04.","journal-title":"Ann Cardiothorac Surg."},{"issue":"9","key":"900_CR2","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1183\/09031936.96.09091932","volume":"9","author":"JC McDonald","year":"1996","unstructured":"McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J. 1996;9(9):1932\u201342. https:\/\/doi.org\/10.1183\/09031936.96.09091932.","journal-title":"Eur Respir J"},{"issue":"5","key":"900_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/oemed-2015-103074","volume":"73","author":"C Gilham","year":"2016","unstructured":"Gilham C, Rake C, Burdett G, Nicholson AG, Davison L, Franchini A, et al. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med. 2016;73(5):290\u20139. https:\/\/doi.org\/10.1136\/oemed-2015-103074.","journal-title":"Occup Environ Med"},{"issue":"Suppl. 2","key":"900_CR4","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.21037\/jtd.2017.10.126","volume":"10","author":"E Pira","year":"2018","unstructured":"Pira E, Donato F, Maida L, Discalzi G. Exposure to asbestos: past, present and future. J Thorac Dis. 2018;10(Suppl. 2):S237\u201345. https:\/\/doi.org\/10.21037\/jtd.2017.10.126.","journal-title":"J Thorac Dis"},{"issue":"16","key":"900_CR5","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.3390\/cancers13164194","volume":"13","author":"F Brims","year":"2021","unstructured":"Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers. 2021;13(16):4194\u2013209. https:\/\/doi.org\/10.3390\/cancers13164194.","journal-title":"Cancers"},{"issue":"1","key":"900_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/occmed\/kqu175","volume":"65","author":"D Sen","year":"2015","unstructured":"Sen D. Working with asbestos and the possible health risks. Occup Med. 2015;65(1):6\u201314. https:\/\/doi.org\/10.1093\/occmed\/kqu175.","journal-title":"Occup Med"},{"issue":"5","key":"900_CR7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/cancers12051186","volume":"12","author":"DM Abbott","year":"2020","unstructured":"Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM. Malignant pleural mesothelioma: genetic and microenviromental heterogeneity as an unexpected reading frame and therapeutic challenge. Cancers (Basel). 2020;12(5):1186\u2013209. https:\/\/doi.org\/10.3390\/cancers12051186.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"900_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/ijerph15030531","volume":"15","author":"LP Allen","year":"2018","unstructured":"Allen LP, Baez J, Stern MEC, Takahashi K, George F. Trends and the economic effect of asbestos bans and decline in asbestos consumption and production worldwide. Int J Environ Res Public Health. 2018;15(3):531\u201340. https:\/\/doi.org\/10.3390\/ijerph15030531.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"900_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/carcin\/bgm023","volume":"28","author":"P Andujar","year":"2007","unstructured":"Andujar P, Lecomte C, Renier A, Fleury-Feith J, Kheuang L, Daubriac J, et al. Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities. Carcinogenesis. 2007;28(7):1599\u2013605. https:\/\/doi.org\/10.1093\/carcin\/bgm023.","journal-title":"Carcinogenesis"},{"issue":"4","key":"900_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.21037\/jtd.2019.03.38","volume":"11","author":"JR Rodr\u00edguez-Cid","year":"2019","unstructured":"Rodr\u00edguez-Cid JR, Garc\u00eda-Acevedo O, Benjamin-Contreras J, Bonilla-Molina D, Flores-Mari\u00f1elarena RR, Mart\u00ednez-Barrera L, et al. Expression of estrogen receptor beta (ER\u03b2) and its prognostic value in pleural mesothelioma. J Thorac Dis. 2019;11(4):1456\u201364. https:\/\/doi.org\/10.21037\/jtd.2019.03.38.","journal-title":"J Thorac Dis"},{"issue":"3","key":"900_CR11","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.21037\/jtd-20-2277","volume":"3","author":"G Pinton","year":"2021","unstructured":"Pinton G, Manzotti B, Balzano C, Moro L. Expression and clinical implications of estrogen receptors in thoracic malignancies: a narrative review. J Thorac Dis. 2021;3(3):1851\u201363. https:\/\/doi.org\/10.21037\/jtd-20-2277.","journal-title":"J Thorac Dis"},{"issue":"6","key":"900_CR12","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1378\/chest.122.6.2224","volume":"122","author":"S Metintas","year":"2002","unstructured":"Metintas S, Metintas M, Ucgun I, Oner U. Malignant Mesothelioma due to Environmental Exposure to Asbestos: follow-up of a Turkish cohort living in a rural area. Chest. 2002;122(6):2224\u20139. https:\/\/doi.org\/10.1378\/chest.122.6.2224.","journal-title":"Chest"},{"issue":"2","key":"900_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2068","volume":"7","author":"M Carbone","year":"2007","unstructured":"Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7(2):147\u201354. https:\/\/doi.org\/10.1038\/nrc2068.","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"900_CR14","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.1073\/pnas.1105887108","volume":"108","author":"M Carbone","year":"2011","unstructured":"Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Nat Acad Sci USA. 2011;108(33):13618\u201323. https:\/\/doi.org\/10.1073\/pnas.1105887108.","journal-title":"Proc Nat Acad Sci USA"},{"issue":"3","key":"900_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/oemed-2013-101957","volume":"72","author":"MA Ortega-Guerrero","year":"2015","unstructured":"Ortega-Guerrero MA, Carrasco-N\u00fa\u00f1ez G, Barrag\u00e1n-Campos H, Ortega MR. High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico. Occup Environ Med. 2015;72(3):216\u20138. https:\/\/doi.org\/10.1136\/oemed-2013-101957.","journal-title":"Occup Environ Med"},{"issue":"12","key":"900_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","volume":"25","author":"DC Hodgson","year":"2007","unstructured":"Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma. J Clin Oncol. 2007;25(12):1489\u201397. https:\/\/doi.org\/10.1200\/JCO.2006.09.0936.","journal-title":"J Clin Oncol"},{"issue":"36","key":"900_CR17","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1200\/JCO.2013.49.9616","volume":"31","author":"LR Chirieac","year":"2013","unstructured":"Chirieac LR, Barletta JA, Yeap BY, Richards WG, Tilleman T, Bueno R, et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013;31(36):4544\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.49.9616.","journal-title":"J Clin Oncol"},{"issue":"8","key":"900_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s10552-013-0230-0","volume":"24","author":"A Farioli","year":"2013","unstructured":"Farioli A, Violante FS, Mattioli S, Curti S, Kriebel D. Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database. Cancer Causes Control. 2013;24(8):1535\u201345. https:\/\/doi.org\/10.1007\/s10552-013-0230-0.","journal-title":"Cancer Causes Control"},{"issue":"12","key":"900_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145039","volume":"10","author":"E Taioli","year":"2015","unstructured":"Taioli E, Wolf AS, Camacho-Rivera M, Kaufman A, Lee DS, Nicastri D, et al. Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLoS ONE. 2015;10(12): e0145039. https:\/\/doi.org\/10.1371\/journal.pone.0145039.","journal-title":"PLoS ONE"},{"key":"900_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2018.07.007","volume":"124","author":"K S\u00fcveg","year":"2018","unstructured":"S\u00fcveg K, Putora PM, Berghmans T, Glatzer M, Kovac V, Cihoric N. Current efforts in research of pleural mesothelioma: an analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2018.07.007.","journal-title":"Lung Cancer"},{"issue":"10026","key":"900_CR21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(15)01238-6.","journal-title":"Lancet"},{"issue":"9","key":"900_CR22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","volume":"13","author":"L Mutti","year":"2018","unstructured":"Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, et al. Scientific advances and new frontiers in mesothelioma therapeutics. J Thorac Oncol. 2018;13(9):1269\u201383. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.011.","journal-title":"J Thorac Oncol"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"175883592097142","DOI":"10.1177\/1758835920971421","volume":"12","author":"H Yang","year":"2020","unstructured":"Yang H, Xu D, Schmid RA, Peng RW. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther Adv Med Oncol. 2020;12:1758835920971421. https:\/\/doi.org\/10.1177\/1758835920971421.","journal-title":"Ther Adv Med Oncol."},{"key":"900_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.748444","volume":"11","author":"BW Johnson","year":"2021","unstructured":"Johnson BW, Takahashi K, Cheng YY. Preclinical models and resources to facilitate basic science research on malignant mesothelioma: a review. Front Oncol. 2021;11: 748444. https:\/\/doi.org\/10.3389\/fonc.2021.748444.","journal-title":"Front Oncol"},{"issue":"10272","key":"900_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8.","journal-title":"Lancet"},{"issue":"2","key":"900_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(18)30765-4.","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"900_CR27","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.21037\/tlcr.2020.02.01","volume":"9","author":"G Gaudino","year":"2020","unstructured":"Gaudino G, Xue J, Yang H. How asbestos and other fibers cause mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl. 1):S39-46. https:\/\/doi.org\/10.21037\/tlcr.2020.02.01.","journal-title":"Transl Lung Cancer Res."},{"issue":"5","key":"900_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/wnan.41","volume":"1","author":"VC Sanchez","year":"2009","unstructured":"Sanchez VC, Pietruska JR, Miselis NR, Hurt RH, Kane AB. Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(5):511\u201329. https:\/\/doi.org\/10.1002\/wnan.41.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol."},{"issue":"1\u20132","key":"900_CR29","first-page":"1","volume":"71","author":"S Toyokuni","year":"2009","unstructured":"Toyokuni S. Mechanisms of asbestos-induced carcinogenesis. Nagoya J Med Sci. 2009;71(1\u20132):1\u201310.","journal-title":"Nagoya J Med Sci"},{"issue":"1\u20134","key":"900_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10937404.2011.556051","volume":"14","author":"SXL Huang","year":"2011","unstructured":"Huang SXL, Jaurand MC, Kamp DW, Whysner J, Hei TK. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev. 2011;14(1\u20134):179\u2013245. https:\/\/doi.org\/10.1080\/10937404.2011.556051.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"900_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-30018-9_201","volume-title":"Systems biology of free radicals and antioxidants","author":"J Miller","year":"2014","unstructured":"Miller J, Thompson J, Shukla A. Asbestos-induced oxidative stress in lung pathogenesis. In: Laher I, editor. Systems biology of free radicals and antioxidants. Berlin: Springer; 2014. https:\/\/doi.org\/10.1007\/978-3-642-30018-9_201."},{"issue":"1","key":"900_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41416-019-0661-9","volume":"122","author":"L Urso","year":"2020","unstructured":"Urso L, Cavallari I, Sharova E, Ciccarese F, Pasello G, Ciminale V. Metabolic rewiring and redox alterations in malignant pleural mesothelioma. Br J Cancer. 2020;122(1):52\u20136. https:\/\/doi.org\/10.1038\/s41416-019-0661-9.","journal-title":"Br J Cancer"},{"issue":"11","key":"900_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/gcc.22670","volume":"57","author":"M Betti","year":"2018","unstructured":"Betti M, Aspesi A, Ferrante D, Sculco M, Righi L, Mirabelli D, et al. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes. Genes Chromosomes Cancer. 2018;57(11):573\u201383. https:\/\/doi.org\/10.1002\/gcc.22670.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"900_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227(1):44\u201358. https:\/\/doi.org\/10.1002\/jcp.22724.","journal-title":"J Cell Physiol"},{"issue":"1","key":"900_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","volume":"189","author":"S Kumar-Singh","year":"1999","unstructured":"Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189(1):72\u20138. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199909)189:1%3c72::AID-PATH401%3e3.0.CO;2-0.","journal-title":"J Pathol"},{"issue":"3","key":"900_CR36","first-page":"1005","volume":"32","author":"M Neri","year":"2012","unstructured":"Neri M, Ugolini D, Boccia S, Canessa PA, Cesario A, Leoncini G, et al. Chemoprevention of asbestos-linked cancers: a systematic review. Anticancer Res. 2012;32(3):1005\u201313.","journal-title":"Anticancer Res"},{"issue":"1","key":"900_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3123\/jemsge.33.4","volume":"33","author":"L Jiang","year":"2011","unstructured":"Jiang L, Toyokuni S. Elucidation of asbestos-induced mesothelial carcinogenesis toward its prevention. Genes Environ. 2011;33(1):4\u20139. https:\/\/doi.org\/10.3123\/jemsge.33.4.","journal-title":"Genes Environ."},{"issue":"10","key":"900_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022\u20135. https:\/\/doi.org\/10.1038\/ng.912.","journal-title":"Nat Genet"},{"issue":"2","key":"900_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","volume":"76","author":"JA Ohar","year":"2016","unstructured":"Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, et al. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res. 2016;76(2):206\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0295.","journal-title":"Cancer Res"},{"issue":"11","key":"900_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21037\/atm.2017.04.29","volume":"5","author":"M Carbone","year":"2017","unstructured":"Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017;5(11):238. https:\/\/doi.org\/10.21037\/atm.2017.04.29.","journal-title":"Ann Transl Med."},{"issue":"10","key":"900_CR41","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","volume":"13","author":"S Arulananda","year":"2018","unstructured":"Arulananda S, Thapa B, Walkiewicz M, Zapparoli GV, Williams DS, Dobrovic A, et al. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1588\u201394. https:\/\/doi.org\/10.1016\/j.jtho.2018.07.015.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"900_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2478\/raon-2019-0016","volume":"53","author":"K Levpuscek","year":"2019","unstructured":"Levpuscek K, Goricar K, Kovac V, Dolzan V, Franko A. The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma. Radiol Oncol. 2019;53(2):206\u201312. https:\/\/doi.org\/10.2478\/raon-2019-0016.","journal-title":"Radiol Oncol"},{"key":"900_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/492608","volume":"2012","author":"H Matsuzaki","year":"2012","unstructured":"Matsuzaki H, Maeda M, Lee S, Nishimura Y, Kumagai-Takei N, Hayashi H, et al. Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol. 2012;2012: 492608. https:\/\/doi.org\/10.1155\/2012\/492608.","journal-title":"J Biomed Biotechnol"},{"issue":"7","key":"900_CR44","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/jcb.24094","volume":"113","author":"JA Tamminen","year":"2012","unstructured":"Tamminen JA, Myll\u00e4rniemi M, Hyyti\u00e4inen M, Keski-Oja J, Koli K. Asbestos exposure induces alveolar epithelial cell plasticity through MAPK\/Erk signaling. J Cell Biochem. 2012;113(7):2234\u201347. https:\/\/doi.org\/10.1002\/jcb.24094.","journal-title":"J Cell Biochem"},{"issue":"14","key":"900_CR45","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.3390\/ijms21145165","volume":"21","author":"M Bonelli","year":"2020","unstructured":"Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, et al. Dual inhibition of CDK4\/6 and PI3K\/AKT\/mTOR signaling impairs energy metabolism in MPM cancer cells. Int J Mol Sci. 2020;21(14):5165\u201381. https:\/\/doi.org\/10.3390\/ijms21145165.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"900_CR46","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1016\/j.cub.2017.09.007","volume":"27","author":"T Chernova","year":"2017","unstructured":"Chernova T, Murphy FA, Galavotti S, Sun XM, Powley IR, Grosso S, et al. Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a (Ink4a\/Arf). Curr Biol. 2017;27(21):3302-14.e6. https:\/\/doi.org\/10.1016\/j.cub.2017.09.007.","journal-title":"Curr Biol"},{"issue":"10","key":"900_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.554570","volume":"14","author":"Y Yoshikawa","year":"2020","unstructured":"Yoshikawa Y, Kuribayashi K, Minami T, Ohmuraya M, Kijima T. Epigenetic alterations and biomarkers for immune checkpoint inhibitors: current standards and future perspectives in malignant pleural mesothelioma treatment. Front Oncol. 2020;14(10): 554570. https:\/\/doi.org\/10.3389\/fonc.2020.554570.","journal-title":"Front Oncol"},{"issue":"19","key":"900_CR48","doi-asserted-by":"publisher","first-page":"16848","DOI":"10.18632\/oncotarget.4253","volume":"6","author":"S Benedetti","year":"2015","unstructured":"Benedetti S, Nuvoli B, Catalani S, Galati R. Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget. 2015;6(19):16848\u201365. https:\/\/doi.org\/10.18632\/oncotarget.4253.","journal-title":"Oncotarget"},{"issue":"41","key":"900_CR49","doi-asserted-by":"publisher","first-page":"25543","DOI":"10.1073\/pnas.2007622117","volume":"117","author":"J Xue","year":"2020","unstructured":"Xue J, Patergnani S, Giorgi C, Suarez J, Goto K, Bononi A, et al. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc Natl Acad Sci USA. 2020;117(41):25543\u201352. https:\/\/doi.org\/10.1073\/pnas.2007622117.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"900_CR50","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.0604008103","volume":"103","author":"H Yang","year":"2006","unstructured":"Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA. 2006;103(27):10397\u2013402. https:\/\/doi.org\/10.1073\/pnas.0604008103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"900_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","volume":"9","author":"A Bononi","year":"2015","unstructured":"Bononi A, Napolitano A, Pass HI, Yang H, Carbone M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med. 2015;9(5):633\u201354. https:\/\/doi.org\/10.1586\/17476348.2015.1081066.","journal-title":"Expert Rev Respir Med"},{"issue":"10","key":"900_CR52","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","volume":"11","author":"M Hylebos","year":"2016","unstructured":"Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol. 2016;11(10):1615\u201326. https:\/\/doi.org\/10.1016\/j.jtho.2016.05.020.","journal-title":"J Thorac Oncol"},{"issue":"5\u20136","key":"900_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10937404.2016.1193361","volume":"19","author":"P Andujar","year":"2016","unstructured":"Andujar P, Lacourt A, Brochard P, Pairon J-C, Jaurand M-C, Jean D. Five years\u2019 update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J Toxicol Environ Health B Crit Rev. 2016;19(5\u20136):151\u201372. https:\/\/doi.org\/10.1080\/10937404.2016.1193361.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"5","key":"900_CR54","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jaad.2014.06.036","volume":"71","author":"M Potrony","year":"2014","unstructured":"Potrony M, Puig-Butill\u00e9 JA, Aguilera P, Badenas C, Carrera C, Malvehy J, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol. 2014;71(5):888\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2014.06.036.","journal-title":"J Am Acad Dermatol"},{"key":"900_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine. 2016;8:30\u20139. https:\/\/doi.org\/10.1016\/j.ebiom.2016.04.017.","journal-title":"EBioMedicine"},{"issue":"7","key":"900_CR56","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413\u20139. https:\/\/doi.org\/10.1093\/carcin\/bgt166.","journal-title":"Carcinogenesis"},{"issue":"12","key":"900_CR57","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1684\/bdc.2013.1857","volume":"100","author":"K Campbell","year":"2013","unstructured":"Campbell K, Brosseau S, Reviron-Rabec L, Bergot E, Lechapt E, Levallet G, Zalcman G. M\u00e9soth\u00e9liomes malins pleuraux: le point en 2013. Bull Cancer. 2013;100(12):1283\u201393. https:\/\/doi.org\/10.1684\/bdc.2013.1857.","journal-title":"Bull Cancer"},{"issue":"1","key":"900_CR58","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12885-019-5652-y","volume":"19","author":"E Kettunen","year":"2019","unstructured":"Kettunen E, Savukoski S, Salmenkivi K, B\u00f6hling T, Vanhala E, Kuosma E, Anttil S, Wolff H. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure. BMC Cancer. 2019;19(1):507. https:\/\/doi.org\/10.1186\/s12885-019-5652-y.","journal-title":"BMC Cancer"},{"issue":"2","key":"900_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/0008-5472.CAN-15-0751","volume":"76","author":"AD De Rienzo","year":"2016","unstructured":"De Rienzo AD, Archer MA, Yeap BY, Dao N, Sciaranghella D, Sideris AC, et al. Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res. 2016;76(2):319\u201328. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0751.","journal-title":"Cancer Res"},{"issue":"42","key":"900_CR60","doi-asserted-by":"publisher","first-page":"72513","DOI":"10.18632\/oncotarget.19872","volume":"8","author":"L Hebert","year":"2017","unstructured":"Hebert L, Bellanger D, Guillas C, Campagne A, Dingli F, Loew D, et al. Modulating BAP1 expression affects ROS homeostasis, cell motility and mitochondrial function. Oncotarget. 2017;8(42):72513\u201327. https:\/\/doi.org\/10.18632\/oncotarget.19872.","journal-title":"Oncotarget"},{"issue":"11","key":"900_CR61","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave LM, B\u00e9guelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344\u20139. https:\/\/doi.org\/10.1038\/nm.3947.","journal-title":"Nat Med"},{"issue":"2","key":"900_CR62","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/PAS.0000000000000976","volume":"42","author":"R Pillappa","year":"2017","unstructured":"Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, et al. Loss of BAP1 expression in atypical mesothelial proliferations helps to predict malignant mesothelioma. Am J Surg Pathol. 2017;42(2):256\u201363. https:\/\/doi.org\/10.1097\/PAS.0000000000000976.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"900_CR63","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","volume":"80","author":"G Srinivasan","year":"2017","unstructured":"Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, et al. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017;80(4):861\u20137. https:\/\/doi.org\/10.1007\/s00280-017-3401-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"28","key":"900_CR64","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863\u201371. https:\/\/doi.org\/10.1200\/JCO.2018.78.5204.","journal-title":"J Clin Oncol"},{"issue":"17","key":"900_CR65","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","volume":"18","author":"M Ladanyi","year":"2012","unstructured":"Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18(17):4485\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2375.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"900_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/gcc.22218","volume":"54","author":"M Betti","year":"2015","unstructured":"Betti M, Casalone E, Ferrante D, Romanelli A, Grosso F, Guarrera S, et al. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer. 2015;54(1):51\u201362. https:\/\/doi.org\/10.1002\/gcc.22218.","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"900_CR67","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","volume":"27","author":"K Oehl","year":"2021","unstructured":"Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, et al. Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res. 2021;27(8):2277\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4037.","journal-title":"Clin Cancer Res"},{"issue":"5660","key":"900_CR68","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"JE Chipuk","year":"2004","unstructured":"Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010\u20134. https:\/\/doi.org\/10.1126\/science.1092734.","journal-title":"Science"},{"issue":"2","key":"900_CR69","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3892\/ijo.18.2.425","volume":"18","author":"T Papp","year":"2001","unstructured":"Papp T, Schipper H, Pemsel H, Bastrop R, Muller KM, Wiethege T, et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol. 2001;18(2):425\u201333. https:\/\/doi.org\/10.3892\/ijo.18.2.425.","journal-title":"Int J Oncol"},{"issue":"3","key":"900_CR70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","volume":"136","author":"JD Daubriac","year":"2012","unstructured":"Daubriac JD, Le Pimpec-Barthes J, Galateau-Salle FF, Jaurand MC. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med. 2012;136(3):277\u201393. https:\/\/doi.org\/10.5858\/arpa.2011-0215-RA.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"900_CR71","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316. https:\/\/doi.org\/10.1038\/ng.3520.","journal-title":"Nat Genet"},{"issue":"7","key":"900_CR72","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/cancers13071561","volume":"13","author":"H Yang","year":"2021","unstructured":"Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, et al. NF2 and canonical Hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural mesothelioma. Cancers (Basel). 2021;13(7):1561\u201384. https:\/\/doi.org\/10.3390\/cancers13071561.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"900_CR73","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1008.","journal-title":"Cancer Res"},{"issue":"6","key":"900_CR74","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel L, Meiller C, Assi\u00e9 JB, Blum Y, Imbeaud S, Montagne F, et al. (Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14(6):1207\u201323. https:\/\/doi.org\/10.1002\/1878-0261.12651.","journal-title":"Mol Oncol"},{"issue":"6","key":"900_CR75","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s13277-012-0473-5","volume":"33","author":"T Hanagiri","year":"2012","unstructured":"Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, et al. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012;33(6):2135\u201341. https:\/\/doi.org\/10.1007\/s13277-012-0473-5.","journal-title":"Tumour Biol"},{"issue":"1","key":"900_CR76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bbrc.2013.09.025","volume":"440","author":"SA Fox","year":"2013","unstructured":"Fox SA, Richards AK, Kusumah I, Perumal V, Bolitho EM, Mutsaers SE, et al. Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells. Biochem Biophys Res Commun. 2013;440(1):82\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2013.09.025.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"900_CR77","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.bbrc.2006.02.084","volume":"2","author":"S Batra","year":"2006","unstructured":"Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun. 2006;2(4):1228\u201332. https:\/\/doi.org\/10.1016\/j.bbrc.2006.02.084.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"900_CR78","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3892\/or_00000875","volume":"24","author":"H Kohno","year":"2010","unstructured":"Kohno H, Amatya VJ, Takeshima Y, Kushitani K, Hattori N, Kohno N, Inai K. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol Rep. 2010;24(2):423\u201331. https:\/\/doi.org\/10.3892\/or_00000875.","journal-title":"Oncol Rep"},{"issue":"2","key":"900_CR79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbcan.2014.01.008","volume":"1845","author":"LVM de Assis","year":"2014","unstructured":"de Assis LVM, Locatelli J, Isoldi MC. The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. Biochim Biophys Acta. 2014;1845(2):232\u201347. https:\/\/doi.org\/10.1016\/j.bbcan.2014.01.008.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"900_CR80","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3892\/ijo.2015.2877","volume":"46","author":"L Guo","year":"2015","unstructured":"Guo L, Teng L. YAP\/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol. 2015;46(4):1444\u201352. https:\/\/doi.org\/10.3892\/ijo.2015.2877.","journal-title":"Int J Oncol"},{"issue":"2","key":"900_CR81","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3760\/cma.j.cn121094-20200831-00505","volume":"39","author":"M Yu","year":"2021","unstructured":"Yu M, Yu M, Zhu LJ, Yuan XY, Zhang X. Expression and clinical significance of SETD2 in maligant pleural mesothelioma. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2021;39(2):91\u20138. https:\/\/doi.org\/10.3760\/cma.j.cn121094-20200831-00505.","journal-title":"Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi"},{"issue":"7","key":"900_CR82","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","volume":"30","author":"K Kawaguchi","year":"2009","unstructured":"Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30(7):1097\u2013105. https:\/\/doi.org\/10.1093\/carcin\/bgp097.","journal-title":"Carcinogenesis"},{"issue":"5","key":"900_CR83","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/jto.0b013e318215a07d","volume":"6","author":"M Brevet","year":"2011","unstructured":"Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. Thorac Oncol. 2011;6(5):864\u201374. https:\/\/doi.org\/10.1097\/jto.0b013e318215a07d.","journal-title":"Thorac Oncol"},{"key":"900_CR84","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","volume":"123","author":"MA Bonelli","year":"2017","unstructured":"Bonelli MA, Fumarola C, La Monica S, Alfieri R. New therapeutic strategies for malignant pleural mesothelioma. Biochem Pharmacol. 2017;123:8\u201318. https:\/\/doi.org\/10.1016\/j.bcp.2016.07.012.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"900_CR85","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1038\/s41467-021-25173-7","volume":"12","author":"S Grosso","year":"2021","unstructured":"Grosso S, Marini A, Gyuraszova K, Voorde JV, Sfakianos A, Garland GD, et al. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat Commun. 2021;12(1):4920\u201337. https:\/\/doi.org\/10.1038\/s41467-021-25173-7.","journal-title":"Nat Commun"},{"issue":"2","key":"900_CR86","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","volume":"51","author":"A Destro","year":"2006","unstructured":"Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, et al. EGFR overexpression in malignant pleural mesothelioma. Lung Cancer. 2006;51(2):207\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2005.10.016.","journal-title":"Lung Cancer"},{"issue":"2","key":"900_CR87","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/PDM.0b013e3182a3645e","volume":"23","author":"V Schildgen","year":"2015","unstructured":"Schildgen V, Pabst O, Tillmann RL, L\u00fcsebrink J, Schildgen O, Ludwig C, et al. Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Appl Immunohistochem Mol Morphol. 2015;23(2):118\u201325. https:\/\/doi.org\/10.1097\/PDM.0b013e3182a3645e.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"900_CR88","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/17425247.2019.1598374","volume":"16","author":"PL Chia","year":"2019","unstructured":"Chia PL, Scott AM, John T. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. Expert Opinion Drug Deliv. 2019;16(4):441\u201351. https:\/\/doi.org\/10.1080\/17425247.2019.1598374.","journal-title":"Expert Opinion Drug Deliv"},{"issue":"5","key":"900_CR89","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","volume":"7","author":"G Broeckx","year":"2018","unstructured":"Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res. 2018;7(5):537\u201342. https:\/\/doi.org\/10.21037\/tlcr.2018.10.04.","journal-title":"Transl Lung Cancer Res."},{"issue":"8","key":"900_CR90","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/bjc.2013.130","volume":"108","author":"R Mezzapelle","year":"2013","unstructured":"Mezzapelle R, Miglio U, Rena O, Paganotti A, Allegrini S, Antona J, et al. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer. 2013;108(8):1743\u20139. https:\/\/doi.org\/10.1038\/bjc.2013.130.","journal-title":"Br J Cancer"},{"issue":"1","key":"900_CR91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","volume":"86","author":"T Shukuya","year":"2014","unstructured":"Shukuya T, Serizawa M, Watanabe M, Akamatsu H, Abe M, Imai H, et al. Identification of actionable mutations in malignant pleural mesothelioma. Lung Cancer. 2014;86(1):35\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2014.08.004.","journal-title":"Lung Cancer"},{"issue":"3","key":"900_CR92","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","volume":"10","author":"M Lo Iacono","year":"2015","unstructured":"Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015;10(3):492\u20139. https:\/\/doi.org\/10.1097\/JTO.0000000000000436.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"900_CR93","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran R, Ma PC, Seiwert T, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66(1):352\u201361. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4567.","journal-title":"Cancer Res"},{"issue":"3","key":"900_CR94","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e3182417da5","volume":"7","author":"G Levallet","year":"2012","unstructured":"Levallet G, Vaisse-Lesteven M, Stang NL, Ilg AGS, Brochard P, Astoul P, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignantmMesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol. 2012;7(3):599\u2013606. https:\/\/doi.org\/10.1097\/JTO.0b013e3182417da5.","journal-title":"J Thorac Oncol"},{"key":"900_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","volume":"23","author":"MC Bois","year":"2016","unstructured":"Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, et al. c-Met expression and MET amplification in malignant pleural mesothelioma. Ann Diagn Pathol. 2016;23:1\u20137. https:\/\/doi.org\/10.1016\/j.anndiagpath.2016.04.007.","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"900_CR96","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","volume":"81","author":"Y Ohta","year":"1999","unstructured":"Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81(1):54\u201361. https:\/\/doi.org\/10.1038\/sj.bjc.6690650.","journal-title":"Br J Cancer"},{"issue":"28","key":"900_CR97","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2217\/fon-2017-0307","volume":"13","author":"S Brosseau","year":"2017","unstructured":"Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G. A review of bevacizumab in the treatment of malignant pleural mesothelioma. Future Oncol. 2017;13(28):2537\u201346. https:\/\/doi.org\/10.2217\/fon-2017-0307.","journal-title":"Future Oncol"},{"key":"900_CR98","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2020.00126","volume":"10","author":"AK Nowak","year":"2020","unstructured":"Nowak AK, Brosseau S, Cook A, Zalcman G. Antiangiogeneic strategies in mesothelioma. Front Oncol. 2020;10:126. https:\/\/doi.org\/10.3389\/fonc.2020.00126.","journal-title":"Front Oncol"},{"issue":"8","key":"900_CR99","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","volume":"316","author":"K Pietras","year":"2010","unstructured":"Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316(8):1324\u201331. https:\/\/doi.org\/10.1016\/j.yexcr.2010.02.045.","journal-title":"Exp Cell Res"},{"issue":"1","key":"900_CR100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39\u201351. https:\/\/doi.org\/10.1016\/j.cell.2010.03.014.","journal-title":"Cell"},{"issue":"1","key":"900_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer immunity cycle. Immunity. 2013;39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"issue":"6","key":"900_CR102","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.3390\/ijms15069519","volume":"15","author":"KA Svokos","year":"2014","unstructured":"Svokos KA, Salhia B, Toms SA. Molecular biology of brain metastasis. Int J Mol Sci. 2014;15(6):9519\u201330. https:\/\/doi.org\/10.3390\/ijms15069519.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"900_CR103","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171\u201386. https:\/\/doi.org\/10.18632\/oncotarget.13895.","journal-title":"Oncotarget"},{"issue":"10","key":"900_CR104","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","volume":"59","author":"N Yamada","year":"2010","unstructured":"Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59(10):1543\u20139. https:\/\/doi.org\/10.1007\/s00262-010-0881-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"900_CR105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21037\/atm.2017.10.12","volume":"5","author":"LF Campesato","year":"2017","unstructured":"Campesato LF, Merghoub T. Antiangiogenic therapy and immune checkpoint blockade go hand in hand. Ann Transl Med. 2017;5(24):497\u2013502. https:\/\/doi.org\/10.21037\/atm.2017.10.12.","journal-title":"Ann Transl Med"},{"key":"900_CR106","doi-asserted-by":"publisher","DOI":"10.1101\/334326","author":"N Alcala","year":"2018","unstructured":"Alcala N, Caux C, Girard N, McKay JD, Galateau-Salle F, Foll M, Fernandez-Cuesta L. Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease. bioRxiv. 2018. https:\/\/doi.org\/10.1101\/334326.","journal-title":"bioRxiv"},{"issue":"4","key":"900_CR107","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/cancers13040658","volume":"13","author":"M Vogl","year":"2021","unstructured":"Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, Ghanim B. Biomarkers for malignant pleural mesothelioma\u2014a novel view on inflammation. Cancers (Basel). 2021;13(4):658. https:\/\/doi.org\/10.3390\/cancers13040658.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"900_CR108","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1009285","volume":"4","author":"H Ujiie","year":"2015","unstructured":"Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4(6): e1009285. https:\/\/doi.org\/10.1080\/2162402X.2015.1009285.","journal-title":"Oncoimmunology"},{"issue":"8","key":"900_CR109","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475\u201388. https:\/\/doi.org\/10.1038\/nrc.2017.42.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"900_CR110","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018;29(5):1258\u201365. https:\/\/doi.org\/10.1093\/annonc\/mdy086.","journal-title":"Ann Oncol"},{"issue":"5","key":"900_CR111","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","volume":"20","author":"S Brosseau","year":"2019","unstructured":"Brosseau S, Danel C, Scherpereel A, Mazi\u00e8res J, Lantuejoul S, Margery J, et al. Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort. Clin Lung Cancer. 2019;20(5):e564\u201375. https:\/\/doi.org\/10.1016\/j.cllc.2019.04.010.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"900_CR112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.210773.112","volume":"27","author":"FX Yu","year":"2013","unstructured":"Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev. 2013;27(4):355\u201371. https:\/\/doi.org\/10.1101\/gad.210773.112.","journal-title":"Genes Dev"},{"issue":"1","key":"900_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.274027.115","volume":"30","author":"Z Meng","year":"2016","unstructured":"Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30(1):1\u201317. https:\/\/doi.org\/10.1101\/gad.274027.115.","journal-title":"Genes Dev"},{"key":"900_CR114","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R, Guan KL. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577\u2013604. https:\/\/doi.org\/10.1146\/annurev-biochem-013118-111829.","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"900_CR115","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/ncb2303","volume":"13","author":"B Zhao","year":"2011","unstructured":"Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13(8):877\u201383. https:\/\/doi.org\/10.1038\/ncb2303.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"900_CR116","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.bbagen.2012.07.005","volume":"1830","author":"SE Hiemer","year":"2013","unstructured":"Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway. Biochem Biophys Acta. 2013;1830(2):2323\u201334. https:\/\/doi.org\/10.1016\/j.bbagen.2012.07.005.","journal-title":"Biochem Biophys Acta"},{"issue":"3","key":"900_CR117","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/genes9030161","volume":"9","author":"S Porazinski","year":"2018","unstructured":"Porazinski S, Ladomery M. Alternative splicing in the Hippo pathway-implications for disease and potential therapeutic targets. Genes (Basel). 2018;9(3):161\u201380. https:\/\/doi.org\/10.3390\/genes9030161.","journal-title":"Genes (Basel)"},{"issue":"4","key":"900_CR118","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.devcel.2012.03.013","volume":"22","author":"JC Boggiano","year":"2012","unstructured":"Boggiano JC, Fehon RG. Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Dev Cell. 2012;22(4):695\u2013702. https:\/\/doi.org\/10.1016\/j.devcel.2012.03.013.","journal-title":"Dev Cell"},{"issue":"1","key":"900_CR119","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tcb.2019.10.005","volume":"30","author":"V Rausch","year":"2020","unstructured":"Rausch V, Hansen CG. The Hippo pathway, YAP\/TAZ, and the plasma membrane. Trends Cell Biol. 2020;30(1):32\u201348. https:\/\/doi.org\/10.1016\/j.tcb.2019.10.005.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"900_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-1869-4","volume":"17","author":"Y Han","year":"2019","unstructured":"Han Y. Analysis of the role of the Hippo pathway in cancer. J Transl Med. 2019;17(1):1\u201317. https:\/\/doi.org\/10.1186\/s12967-019-1869-4.","journal-title":"J Transl Med"},{"issue":"5","key":"900_CR121","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.trecan.2019.04.001","volume":"5","author":"PC Calses","year":"2019","unstructured":"Calses PC, Crawford JJ, Lill JR, Dey A. Hippo Pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019;5(5):297\u2013307. https:\/\/doi.org\/10.1016\/j.trecan.2019.04.001.","journal-title":"Trends Cancer"},{"issue":"6","key":"900_CR122","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/1878-0261.12498","volume":"13","author":"M Shreberk-Shaked","year":"2019","unstructured":"Shreberk-Shaked M, Oren M. New insights into YAP\/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities? Mol Oncol. 2019;13(6):1335\u201341. https:\/\/doi.org\/10.1002\/1878-0261.12498.","journal-title":"Mol Oncol"},{"issue":"11","key":"900_CR123","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.cellsig.2016.08.004","volume":"28","author":"HJ Janse van Rensburg","year":"2016","unstructured":"Janse van Rensburg HJ, Yang X. The roles of the Hippo pathway in cancer metastasis. Cell Signaling. 2016;28(11):1761\u201372. https:\/\/doi.org\/10.1016\/j.cellsig.2016.08.004.","journal-title":"Cell Signaling"},{"issue":"3","key":"900_CR124","first-page":"311","volume":"68","author":"AL Zygulska","year":"2017","unstructured":"Zygulska AL, Krzemieniecki K, Pierzchalski P. Hippo pathway\u2014brief overview of its relevance in cancer. J Physiol Pharmacol. 2017;68(3):311\u201335.","journal-title":"J Physiol Pharmacol"},{"issue":"7","key":"900_CR125","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/bies.201600037","volume":"38","author":"A Elbediwy","year":"2016","unstructured":"Elbediwy A, Vincent-Mistiaen ZI, Thompson BJ. YAP and TAZ in epithelial stem cells: a sensor for cell polarity, mechanical forces and tissue damage. BioEssays. 2016;38(7):644\u201353. https:\/\/doi.org\/10.1002\/bies.201600037.","journal-title":"BioEssays"},{"issue":"1","key":"900_CR126","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/2045-3701-3-33","volume":"3","author":"X Guo","year":"2013","unstructured":"Guo X, Zhao B. Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. Cell Biosci. 2013;3(1):33\u201342. https:\/\/doi.org\/10.1186\/2045-3701-3-33.","journal-title":"Cell Biosci"},{"issue":"6","key":"900_CR127","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1073\/pnas.1420850112","volume":"112","author":"CC Yang","year":"2015","unstructured":"Yang CC, Graves HK, Moya IM, Tao C, Hamaratoglu F, et al. Differential regulation of the Hippo pathway by adherens junctions and apical\u2013basal cell polarity modules. Proc Natl Acad Sci USA. 2015;112(6):1785\u201390. https:\/\/doi.org\/10.1073\/pnas.1420850112.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"900_CR128","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.devcel.2010.11.012","volume":"19","author":"X Varelas","year":"2010","unstructured":"Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. The crumbs complex couples cell density sensing to hippo-dependent control of the TGF-\u03b2-SMAD pathway. Dev Cell. 2010;19(6):831\u201344. https:\/\/doi.org\/10.1016\/j.devcel.2010.11.012.","journal-title":"Dev Cell"},{"issue":"1","key":"900_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.478","volume":"8","author":"X Mao","year":"2017","unstructured":"Mao X, Li P, Wang Y, Liang Z, Liu J, Li J, et al. CRB3 regulates contact inhibition by activating the Hippo pathway in mammary epithelial cells. Cell Death Dis. 2017;8(1): e2546. https:\/\/doi.org\/10.1038\/cddis.2016.478.","journal-title":"Cell Death Dis"},{"issue":"4","key":"900_CR130","doi-asserted-by":"publisher","first-page":"7073","DOI":"10.1111\/febs.15710","volume":"288","author":"E Martin","year":"2021","unstructured":"Martin E, Girardello R, Dittmar G, Ludwig A. New insights into the organization and regulation of the apical polarity network in mammalian epithelial cells. FEBS J. 2021;288(4):7073\u201395. https:\/\/doi.org\/10.1111\/febs.15710.","journal-title":"FEBS J"},{"issue":"8","key":"900_CR131","doi-asserted-by":"publisher","first-page":"975","DOI":"10.15252\/embr.201439951","volume":"16","author":"XB Lv","year":"2015","unstructured":"Lv XB, Liu CY, Wang Z, Sun YP, Xiong Y, Lei QY, Guan KL. PARD3 induces TAZ activation and cell growth by promoting LATS1 and PP1 interaction. EMBO Rep. 2015;16(8):975\u201385. https:\/\/doi.org\/10.15252\/embr.201439951.","journal-title":"EMBO Rep"},{"issue":"2","key":"900_CR132","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.devcel.2009.12.011","volume":"18","author":"A Genevet","year":"2010","unstructured":"Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador\/Warts\/Hippo signaling network. Dev Cell. 2010;18(2):300\u20138. https:\/\/doi.org\/10.1016\/j.devcel.2009.12.011.","journal-title":"Dev Cell"},{"issue":"2","key":"900_CR133","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.devcel.2009.12.012","volume":"18","author":"J Yu","year":"2010","unstructured":"Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell. 2010;18(2):288\u201399. https:\/\/doi.org\/10.1016\/j.devcel.2009.12.012.","journal-title":"Dev Cell"},{"issue":"10","key":"900_CR134","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1074\/jbc.M110.173468","volume":"286","author":"L Xiao","year":"2011","unstructured":"Xiao L, Chen Y, Ji M, Dong J. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem. 2011;286(10):7788\u201396. https:\/\/doi.org\/10.1074\/jbc.M110.173468.","journal-title":"J Biol Chem"},{"issue":"9","key":"900_CR135","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1074\/jbc.C110.212621","volume":"286","author":"SW Chan","year":"2011","unstructured":"Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by Angiomotin. J Biol Chem. 2011;286(9):7018\u201326. https:\/\/doi.org\/10.1074\/jbc.C110.212621.","journal-title":"J Biol Chem"},{"key":"900_CR136","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1038\/ncomms12133","volume":"7","author":"CY Li","year":"2016","unstructured":"Li CY, Lu H, Hu J, Lan J, Galicia N, Klein OD, Du W. \u03b1E-catenin inhibits YAP\/TAZ activity to regulate signalling centre formation during tooth development. Nat Commun. 2016;7:12133. https:\/\/doi.org\/10.1038\/ncomms12133.","journal-title":"Nat Commun"},{"issue":"7","key":"900_CR137","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1101\/gad.274951.115","volume":"30","author":"P Li","year":"2016","unstructured":"Li P, Silvis MR, Honaker Y, Lien W-H, Arron ST, Vasioukhin V. \u03b1E-catenin inhibits a Src\u2013YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev. 2016;30(7):798\u2013811. https:\/\/doi.org\/10.1101\/gad.274951.115.","journal-title":"Genes Dev"},{"issue":"4","key":"900_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061916","volume":"8","author":"C Michaloglou","year":"2013","unstructured":"Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS ONE. 2013;8(4): e61916. https:\/\/doi.org\/10.1371\/journal.pone.0061916.","journal-title":"PLoS ONE"},{"issue":"17","key":"900_CR139","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1101\/gad.192955.112","volume":"26","author":"W Wang","year":"2012","unstructured":"Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, et al. PTPN14 is required for the density-dependent control of YAP1. Genes Dev. 2012;26(17):1959\u201371. https:\/\/doi.org\/10.1101\/gad.192955.112.","journal-title":"Genes Dev"},{"key":"900_CR140","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fonc.2015.00190","volume":"5","author":"MD Deel","year":"2015","unstructured":"Deel MD, Li JJ, Crose LES, Linardic CM. A review: molecular aberrations within Hippo signaling in bone and soft-tissue sarcomas. Front Oncol. 2015;5:190. https:\/\/doi.org\/10.3389\/fonc.2015.00190.","journal-title":"Front Oncol"},{"issue":"6","key":"900_CR141","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-15-1008","volume":"76","author":"F Dubois","year":"2016","unstructured":"Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A, et al. RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1\/RhoB pathway. Can Res. 2016;76(6):1627\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1008.","journal-title":"Can Res"},{"issue":"7","key":"900_CR142","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1158\/0008-5472.CAN-15-1752","volume":"76","author":"MG Lee","year":"2016","unstructured":"Lee MG, Jeong SI, Ko KP, Park SK, Ryu BK, Kim IY, et al. RASSF1A directly antagonizes RhoA activity through the assembly of a Smurf1-mediated destruction complex to suppress tumorigenesis. Can Res. 2016;76(7):1847\u201359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1752.","journal-title":"Can Res"},{"issue":"7350","key":"900_CR143","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474(7350):179\u201383. https:\/\/doi.org\/10.1038\/nature10137.","journal-title":"Nature"},{"issue":"10","key":"900_CR144","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1016\/j.celrep.2017.02.041","volume":"18","author":"S Chakraborty","year":"2017","unstructured":"Chakraborty S, Njah K, Pobbati AV, Lim YB, Raju A, Lakshmanan M, et al. Agrin as a mechanotransduction signal regulating YAP through the Hippo Pathway. Cell Rep. 2017;18(10):2464\u201379. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.041.","journal-title":"Cell Rep"},{"issue":"5","key":"900_CR145","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fern\u00e1ndez-Valle C. Role of Merlin\/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537\u201348. https:\/\/doi.org\/10.1038\/onc.2015.125.","journal-title":"Oncogene"},{"issue":"8","key":"900_CR146","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.189601","volume":"15","author":"H Morrison","year":"2001","unstructured":"Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001;15(8):968\u201380. https:\/\/doi.org\/10.1101\/gad.189601.","journal-title":"Genes Dev"},{"issue":"44","key":"900_CR147","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006;25(44):5960\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1209587.","journal-title":"Oncogene"},{"issue":"237","key":"900_CR148","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra68. https:\/\/doi.org\/10.1126\/scitranslmed.3008639.","journal-title":"Sci Transl Med"},{"issue":"1","key":"900_CR149","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12964-020-00544-7","volume":"18","author":"M Mota","year":"2020","unstructured":"Mota M, Shevde LA. Merlin regulates signaling events at the nexus of development and cancer. Cell Commun Signal. 2020;18(1):63\u201371. https:\/\/doi.org\/10.1186\/s12964-020-00544-7.","journal-title":"Cell Commun Signal"},{"issue":"7\u20138","key":"900_CR150","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1101\/gad.333435.119","volume":"34","author":"AW Hong","year":"2020","unstructured":"Hong AW, Meng Z, Plouffe SW, Lin Z, Zhang M, Guan KL. Critical roles of phosphoinositides and NF2 in Hippo pathway regulation. Genes Dev. 2020;34(7\u20138):511\u201325. https:\/\/doi.org\/10.1101\/gad.333435.119.","journal-title":"Genes Dev"},{"issue":"10","key":"900_CR151","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedr\u00e9s S, Nolan L, Kindler H, Aerts JGJV. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-a double-blind, randomized, phase II study. J Clin Oncol. 2019;37(10):790\u20138. https:\/\/doi.org\/10.1200\/JCO.2018.79.0543.","journal-title":"J Clin Oncol"},{"key":"900_CR152","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.23.465573","author":"F Haderk","year":"2022","unstructured":"Haderk F, Fern\u00e1ndez-M\u00e9ndez C, \u010cech L, Yu J, Meraz IM, Olivas V, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer. BioRxiv. 2022. https:\/\/doi.org\/10.1101\/2021.10.23.465573.","journal-title":"BioRxiv"},{"issue":"8","key":"900_CR153","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-20-1027","volume":"16","author":"J Cooper","year":"2017","unstructured":"Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss-driven tumorigenesis. Mol Cancer Therap. 2017;16(8):1693\u2013704. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-1027.","journal-title":"Mol Cancer Therap."},{"issue":"4","key":"900_CR154","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/mp.52.4.189","volume":"52","author":"S Goodison","year":"1999","unstructured":"Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999;52(4):189\u201396. https:\/\/doi.org\/10.1136\/mp.52.4.189.","journal-title":"Mol Pathol"},{"issue":"21","key":"900_CR155","doi-asserted-by":"publisher","first-page":"20310","DOI":"10.1074\/jbc.M500737200","volume":"280","author":"S Misra","year":"2005","unstructured":"Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem. 2005;280(21):20310\u20135. https:\/\/doi.org\/10.1074\/jbc.M500737200.","journal-title":"J Biol Chem"},{"key":"900_CR156","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s0065-230x(08)60101-3","volume":"71","author":"D Naor","year":"1997","unstructured":"Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241\u2013319. https:\/\/doi.org\/10.1016\/s0065-230x(08)60101-3.","journal-title":"Adv Cancer Res"},{"issue":"3","key":"900_CR157","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/1535370213480714","volume":"238","author":"K Williams","year":"2013","unstructured":"Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood, NJ). 2013;238(3):324\u201338. https:\/\/doi.org\/10.1177\/1535370213480714.","journal-title":"Exp Biol Med (Maywood, N.J.)"},{"issue":"12","key":"900_CR158","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1369\/jhc.7A7270.2007","volume":"55","author":"P Karihtala","year":"2007","unstructured":"Karihtala P, Soini Y, Auvinen P, Tammi R, Tammi M, Kosma VM. Hyaluronan and breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem. 2007;55(12):1191\u20138. https:\/\/doi.org\/10.1369\/jhc.7A7270.2007.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"900_CR159","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64\u201387. https:\/\/doi.org\/10.1186\/s13045-018-0605-5.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"900_CR160","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/jid.2009.13","volume":"129","author":"I Stamenkovic","year":"2009","unstructured":"Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Investig Dermatol. 2009;129(6):1321\u20134. https:\/\/doi.org\/10.1038\/jid.2009.13.","journal-title":"J Investig Dermatol"},{"issue":"25","key":"900_CR161","doi-asserted-by":"publisher","first-page":"17635","DOI":"10.1074\/jbc.M800109200","volume":"283","author":"LYW Bourguignon","year":"2008","unstructured":"Bourguignon LYW, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker nanog, stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283(25):17635\u201351. https:\/\/doi.org\/10.1074\/jbc.M800109200.","journal-title":"J Biol Chem"},{"issue":"24","key":"900_CR162","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-09-0479","volume":"15","author":"BP Toole","year":"2009","unstructured":"Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res. 2009;15(24):7462\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0479.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"900_CR163","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1101\/gad.242602","volume":"16","author":"V Orian-Rousseau","year":"2002","unstructured":"Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF\/c-Met signaling. Genes Dev. 2002;16(23):3074\u201386. https:\/\/doi.org\/10.1101\/gad.242602.","journal-title":"Genes Dev"},{"issue":"6","key":"900_CR164","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3892\/ijmm.2020.4562","volume":"45","author":"J Yin","year":"2020","unstructured":"Yin J, Zhang H, Wu X, Zhang Y, Li J, Shen J, et al. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild-type non-small-cell lung cancer cells. Int J Mol Med. 2020;45(6):1783\u201392. https:\/\/doi.org\/10.3892\/ijmm.2020.4562.","journal-title":"Int J Mol Med"},{"issue":"2","key":"900_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188437","volume":"1874","author":"SPJ Joosten","year":"2020","unstructured":"Joosten SPJ, Spaargaren M, Clevers H, Pals ST. Hepatocyte growth factor\/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. Biochimica et biophysica acta Rev Cancer. 2020;1874(2): 188437. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188437.","journal-title":"Biochimica et biophysica acta. Rev Cancer"},{"key":"900_CR166","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-800092-2.00010-1","volume-title":"Advances in cancer research","author":"LYW Bourguignon","year":"2014","unstructured":"Bourguignon LYW, Shiina M, Li JJ. Chapter ten\u2014hyaluronan\u2013CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. In: Simpson MA, Heldin P, editors. Advances in cancer research, vol. 123. Amsterdam: Elsevier; 2014. p. 255\u201375. https:\/\/doi.org\/10.1016\/B978-0-12-800092-2.00010-1."},{"issue":"10","key":"900_CR167","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/gtc.12276","volume":"20","author":"S Terawaki","year":"2015","unstructured":"Terawaki S, Kitano K, Aoyama M, Mori T, Hakoshima T. MT1-MMP recognition by ERM proteins and its implication in CD44 shedding. Genes Cells. 2015;20(10):847\u201359. https:\/\/doi.org\/10.1111\/gtc.12276.","journal-title":"Genes Cells"},{"issue":"10","key":"900_CR168","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1096\/fj.202000380RR","volume":"34","author":"L Chen","year":"2020","unstructured":"Chen L, Fu C, Zhang Q, He C, Zhang F, Wei Q. The role of CD44 in pathological angiogenesis. FASEB J. 2020;34(10):13125\u201339. https:\/\/doi.org\/10.1096\/fj.202000380RR.","journal-title":"FASEB J"},{"key":"900_CR169","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fimmu.2015.00154","volume":"6","author":"V Orian-Rousseau","year":"2015","unstructured":"Orian-Rousseau V. CD44 acts as a signaling platform controlling tumor progression and metastasis. Front Immunol. 2015;6:154. https:\/\/doi.org\/10.3389\/fimmu.2015.00154.","journal-title":"Front Immunol"},{"key":"900_CR170","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fcell.2017.00018","volume":"5","author":"LT Senbanjo","year":"2017","unstructured":"Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18\u201324. https:\/\/doi.org\/10.3389\/fcell.2017.00018.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"900_CR171","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/sj.onc.1209849","volume":"26","author":"Y Bai","year":"2007","unstructured":"Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene. 2007;26(6):836\u201350. https:\/\/doi.org\/10.1038\/sj.onc.1209849.","journal-title":"Oncogene"},{"issue":"6","key":"900_CR172","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-09-2505","volume":"70","author":"Y Xu","year":"2010","unstructured":"Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma. Can Res. 2010;70(6):2455\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2505.","journal-title":"Can Res"},{"issue":"4","key":"900_CR173","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.devcel.2019.04.018","volume":"49","author":"T Ooki","year":"2019","unstructured":"Ooki T, Murata-Kamiya N, Takahashi-Kanemitsu A, Wu W, Hatakeyama M. High-molecular-weight hyaluronan is a hippo pathway ligand directing cell density-dependent growth inhibition via PAR1b. Dev Cell. 2019;49(4):590\u2013604. https:\/\/doi.org\/10.1016\/j.devcel.2019.04.018.","journal-title":"Dev Cell"},{"issue":"Pt 18","key":"900_CR174","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1242\/jcs.010389","volume":"120","author":"H Donninger","year":"2007","unstructured":"Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120(Pt 18):3163\u201372. https:\/\/doi.org\/10.1242\/jcs.010389.","journal-title":"J Cell Sci"},{"issue":"9","key":"900_CR175","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1158\/0008-5472.CAN-04-4088","volume":"65","author":"A Agathanggelou","year":"2005","unstructured":"Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Can Res. 2005;65(9):3497\u2013508. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4088.","journal-title":"Can Res"},{"issue":"12","key":"900_CR176","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41419-019-2169-x","volume":"10","author":"F Dubois","year":"2019","unstructured":"Dubois F, Bergot E, Zalcman G, Levallet G. RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis\u2014an updated review. Cell Death Dis. 2019;10(12):928\u201341. https:\/\/doi.org\/10.1038\/s41419-019-2169-x.","journal-title":"Cell Death Dis"},{"issue":"1","key":"900_CR177","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13046-019-1145-8","volume":"38","author":"M Keller","year":"2019","unstructured":"Keller M, Dubois F, Teulier S, Martin APJ, Levallet J, Maille E, et al. NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. J Exp Clin Cancer Res. 2019;38(1):158\u201374. https:\/\/doi.org\/10.1186\/s13046-019-1145-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"900_CR178","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.trecan.2019.10.001","volume":"5","author":"F Dubois","year":"2019","unstructured":"Dubois F, Bergot E, Levallet G. Cancer and RASSF1A\/RASSF1C, the Two Faces of Janus. Trends Cancer. 2019;5(11):662\u20135. https:\/\/doi.org\/10.1016\/j.trecan.2019.10.001.","journal-title":"Trends Cancer"},{"issue":"9","key":"900_CR179","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1074\/jbc.M709037200","volume":"283","author":"Y Hao","year":"2008","unstructured":"Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008;283(9):5496\u2013509. https:\/\/doi.org\/10.1074\/jbc.M709037200.","journal-title":"J Biol Chem"},{"key":"900_CR180","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2001-1326-3-22","volume":"3","author":"M Gomez","year":"2014","unstructured":"Gomez M, Gomez V, Hergovich A. The Hippo pathway in disease and therapy: cancer and beyond. Clin Transl Med. 2014;3:22\u201334. https:\/\/doi.org\/10.1186\/2001-1326-3-22.","journal-title":"Clin Transl Med"},{"issue":"1\u20132","key":"900_CR181","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0378-1119(95)00653-2","volume":"167","author":"CL Creasy","year":"1995","unstructured":"Creasy CL, Chernoff J. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene. 1995;167(1\u20132):303\u20136. https:\/\/doi.org\/10.1016\/0378-1119(95)00653-2.","journal-title":"Gene"},{"issue":"8","key":"900_CR182","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/cgt.2013.40","volume":"20","author":"CM Xu","year":"2013","unstructured":"Xu CM, Liu WW, Liu CJ, Wen C, Lu HF, Wan FS. Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo. Cancer Gene Ther. 2013;20(8):453\u201360. https:\/\/doi.org\/10.1038\/cgt.2013.40.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"900_CR183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41590-018-0284-y","volume":"20","author":"LA Dempsey","year":"2019","unstructured":"Dempsey LA. Mst kinase roles. Nat Immunol. 2019;20(1):1. https:\/\/doi.org\/10.1038\/s41590-018-0284-y.","journal-title":"Nat Immunol"},{"issue":"8","key":"900_CR184","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ncb2537","volume":"14","author":"M Gloerich","year":"2012","unstructured":"Gloerich M, Ten Klooster JP, Vliem MJ, Koorman T, Zwartkruis FJ, Clevers H, Bos JL. Rap2A links intestinal cell polarity to brush border formation. Nat Cell Biol. 2012;14(8):793\u2013801. https:\/\/doi.org\/10.1038\/ncb2537.","journal-title":"Nat Cell Biol"},{"issue":"24","key":"900_CR185","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1242\/jcs.198614","volume":"129","author":"FK Mardakheh","year":"2016","unstructured":"Mardakheh FK, Self A, Marshall CJ. RHO binding to FAM65A regulates Golgi reorientation during cell migration. J Cell Sci. 2016;129(24):4466\u201379. https:\/\/doi.org\/10.1242\/jcs.198614.","journal-title":"J Cell Sci"},{"issue":"7","key":"900_CR186","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1083\/jcb.200310061","volume":"164","author":"C Preisinger","year":"2004","unstructured":"Preisinger C, Short B, De Corte V, Bruyneel E, Haas A, Kopajtich R, et al. YSK1 is activated by the Golgi matrix protein GM130 and plays a role in cell migration through its substrate 14\u20133-3\u03b6. J Cell Biol. 2004;164(7):1009\u201320. https:\/\/doi.org\/10.1083\/jcb.200310061.","journal-title":"J Cell Biol"},{"issue":"6","key":"900_CR187","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1083\/jcb.201507005","volume":"210","author":"BJ Thompson","year":"2015","unstructured":"Thompson BJ, Sahai E. MST kinases in development and disease. J Cell Biol. 2015;210(6):871\u201382. https:\/\/doi.org\/10.1083\/jcb.201507005.","journal-title":"J Cell Biol"},{"issue":"3","key":"900_CR188","first-page":"357","volume":"23","author":"X Luo","year":"2009","unstructured":"Luo X, Li Z, Yan Q, Li X, Tao D, Wang J, et al. The human WW45 protein enhances MST1-mediated apoptosis in vivo. Int J Mol Med. 2009;23(3):357\u201362.","journal-title":"Int J Mol Med"},{"issue":"8","key":"900_CR189","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/emboj\/17.8.2224","volume":"17","author":"JD Graves","year":"1998","unstructured":"Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DK, Wright M, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J. 1998;17(8):2224\u201334. https:\/\/doi.org\/10.1093\/emboj\/17.8.2224.","journal-title":"EMBO J"},{"issue":"7","key":"900_CR190","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.semcdb.2012.07.002","volume":"23","author":"J Avruch","year":"2012","unstructured":"Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR. Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol. 2012;23(7):770\u201384. https:\/\/doi.org\/10.1016\/j.semcdb.2012.07.002.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"900_CR191","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0014-5793(03)00474-5","volume":"546","author":"R Tamaskovic","year":"2003","unstructured":"Tamaskovic R, Bichsel SJ, Hemmings BA. NDR family of AGC kinases\u2013essential regulators of the cell cycle and morphogenesis. FEBS Lett. 2003;546(1):73\u201380. https:\/\/doi.org\/10.1016\/s0014-5793(03)00474-5.","journal-title":"FEBS Lett"},{"issue":"1","key":"900_CR192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm2822","volume":"11","author":"LR Pearce","year":"2010","unstructured":"Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010;11(1):9\u201322. https:\/\/doi.org\/10.1038\/nrm2822.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"900_CR193","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.semcancer.04.010","volume":"48","author":"AAD Sharif","year":"2018","unstructured":"Sharif AAD, Hergovich A. The NDR\/LATS protein kinases in immunology and cancer biology. Semin Cancer Biol. 2018;48:104\u201314. https:\/\/doi.org\/10.1016\/j.semcancer.04.010.","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"900_CR194","doi-asserted-by":"publisher","first-page":"23806","DOI":"10.1074\/jbc.M402472200","volume":"279","author":"MR Stegert","year":"2004","unstructured":"Stegert MR, Tamaskovic R, Bichsel SJ, Hergovich A, Hemmings BA. Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein. J Biol Chem. 2004;279(22):23806\u201312. https:\/\/doi.org\/10.1074\/jbc.M402472200.","journal-title":"J Biol Chem"},{"issue":"1","key":"900_CR195","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2045-3701-3-32","volume":"3","author":"A Hergovich","year":"2013","unstructured":"Hergovich A. Regulation and functions of mammalian LATS\/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci. 2013;3(1):32\u201344. https:\/\/doi.org\/10.1186\/2045-3701-3-32.","journal-title":"Cell Biosci"},{"issue":"3","key":"900_CR196","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/cr.2014.10","volume":"24","author":"W Zhang","year":"2014","unstructured":"Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331\u201343. https:\/\/doi.org\/10.1038\/cr.2014.10.","journal-title":"Cell Res"},{"issue":"7108","key":"900_CR197","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nature05090","volume":"443","author":"K Emoto","year":"2006","unstructured":"Emoto K, Parrish JZ, Jan LY, Jan YN. The tumour suppressor Hippo acts with the NDR kinases in dendritic tiling and maintenance. Nature. 2006;443(7108):210\u20133. https:\/\/doi.org\/10.1038\/nature05090.","journal-title":"Nature"},{"issue":"23","key":"900_CR198","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.cub.2008.10.060","volume":"18","author":"A Vichalkovski","year":"2008","unstructured":"Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, Hemmings BA. NDR kinase is activated by RASSF1A\/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol. 2008;18(23):1889\u201395. https:\/\/doi.org\/10.1016\/j.cub.2008.10.060.","journal-title":"Curr Biol"},{"issue":"8","key":"900_CR199","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cub.2009.02.054","volume":"19","author":"S Chiba","year":"2009","unstructured":"Chiba S, Ikeda M, Katsunuma K, Ohashi K, Mizuno K. MST2- and Furry-mediated activation of NDR1 kinase is critical for precise alignment of mitotic chromosomes. Curr Biol. 2009;19(8):675\u201381. https:\/\/doi.org\/10.1016\/j.cub.2009.02.054.","journal-title":"Curr Biol"},{"issue":"12","key":"900_CR200","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.4161\/cc.10.12.15826","volume":"10","author":"H Cornils","year":"2011","unstructured":"Cornils H, Kohler RS, Hergovich A, Hemmings BA. (Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. Cell Cycle. 2011;10(12):1897\u2013904. https:\/\/doi.org\/10.4161\/cc.10.12.15826.","journal-title":"Cell Cycle"},{"issue":"6","key":"900_CR201","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/emboj.2013.32","volume":"32","author":"S Chiba","year":"2013","unstructured":"Chiba S, Amagai Y, Homma Y, Fukuda M, Mizuno K. NDR2-mediated Rabin8 phosphorylation is crucial for ciliogenesis by switching binding specificity from phosphatidylserine to Sec15. EMBO J. 2013;32(6):874\u201385. https:\/\/doi.org\/10.1038\/emboj.2013.32.","journal-title":"EMBO J"},{"issue":"19","key":"900_CR202","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.cub.2015.08.031","volume":"25","author":"C Joffre","year":"2005","unstructured":"Joffre C, Dupont N, Hoa L, Gomez V, Pardo R, Gon\u00e7alves-Pimentel C, et al. The pro-apoptotic STK38 kinase is a new Beclin1 partner positively regulating autophagy. Curr Biol. 2005;25(19):2479\u201392. https:\/\/doi.org\/10.1016\/j.cub.2015.08.031.","journal-title":"Curr Biol"},{"key":"900_CR203","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3389\/fimmu.2020.00534","volume":"11","author":"X Ye","year":"2020","unstructured":"Ye X, Ong N, An H, Zheng Y. The emerging roles of NDR1\/2 in infection and inflammation. Front Immunol. 2020;11:534. https:\/\/doi.org\/10.3389\/fimmu.2020.00534.","journal-title":"Front Immunol"},{"issue":"12","key":"900_CR204","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1038\/sj.onc.1208445","volume":"24","author":"EHY Chan","year":"2005","unstructured":"Chan EHY, Nousiainen M, Chalamalasetty RB, Sch\u00e4fer A, Nigg EA, Sillj\u00e9 HHW. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24(12):2076\u201386. https:\/\/doi.org\/10.1038\/sj.onc.1208445.","journal-title":"Oncogene"},{"issue":"5","key":"900_CR205","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1083\/jcb.149.5.1073","volume":"149","author":"T Hirota","year":"2000","unstructured":"Hirota T, Morisaki T, Nishiyama Y, Marumoto T, Tada K, Hara T, et al. Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with H-warts\/Lats1 tumor suppressor. J Cell Biol. 2000;149(5):1073\u201386. https:\/\/doi.org\/10.1083\/jcb.149.5.1073.","journal-title":"J Cell Biol"},{"issue":"9","key":"900_CR206","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/cdd.2017.99","volume":"24","author":"N Furth","year":"2017","unstructured":"Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24(9):1488\u2013501. https:\/\/doi.org\/10.1038\/cdd.2017.99.","journal-title":"Cell Death Differ"},{"key":"900_CR207","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fcell.2020.00161","volume":"8","author":"JC Duhart","year":"2020","unstructured":"Duhart JC, Raftery LA. Mob family proteins: regulatory partners in Hippo and Hippo-like intracellular signalingpPathways. Front Cell Devel Biol. 2020;8:161\u201383. https:\/\/doi.org\/10.3389\/fcell.2020.00161.","journal-title":"Front Cell Devel Biol."},{"issue":"9","key":"900_CR208","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.cellsig.2011.04.007","volume":"23","author":"A Hergovich","year":"2011","unstructured":"Hergovich A. MOB control: reviewing a conserved family of kinase regulators. Cell Signal. 2011;23(9):1433\u201340. https:\/\/doi.org\/10.1016\/j.cellsig.2011.04.007.","journal-title":"Cell Signal"},{"issue":"5","key":"900_CR209","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cub.2008.02.006","volume":"18","author":"M Praskova","year":"2008","unstructured":"Praskova M, Xia F, Avruch J. (MOBKL1A\/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol. 2008;18(5):311\u201321. https:\/\/doi.org\/10.1016\/j.cub.2008.02.006.","journal-title":"Curr Biol"},{"issue":"13","key":"900_CR210","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1101\/gad.264929.115","volume":"29","author":"L Ni","year":"2015","unstructured":"Ni L, Zheng Y, Hara M, Pan D, Luo X. Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling. Genes Dev. 2015;29(13):1416\u201331. https:\/\/doi.org\/10.1101\/gad.264929.115.","journal-title":"Genes Dev"},{"key":"900_CR211","doi-asserted-by":"publisher","first-page":"28488","DOI":"10.1038\/srep28488","volume":"6","author":"SY Kim","year":"2016","unstructured":"Kim SY, Tachioka Y, Mori T, Hakoshima T. Structural basis for autoinhibition and its relief of MOB1 in the Hippo pathway. Sci Rep. 2016;6:28488. https:\/\/doi.org\/10.1038\/srep28488.","journal-title":"Sci Rep"},{"issue":"6","key":"900_CR212","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1074\/mcp.M116.065490","volume":"16","author":"AL Couzens","year":"2017","unstructured":"Couzens AL, Xiong S, Knight JDR, Mao DY, Guettler S, Picaud S, et al. MOB1 mediated phospho-recognition in the core mammalian Hippo pathway. Mol Cell Proteomics. 2017;16(6):1098\u2013110. https:\/\/doi.org\/10.1074\/mcp.M116.065490.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"900_CR213","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1042\/BST20110619","volume":"40","author":"A Hergovich","year":"2012","unstructured":"Hergovich A. Mammalian Hippo signalling: a kinase network regulated by protein\u2013protein interactions. Biochem Soc Trans. 2012;40(1):124\u20138. https:\/\/doi.org\/10.1042\/BST20110619.","journal-title":"Biochem Soc Trans"},{"issue":"18","key":"900_CR214","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1128\/MCB.00150-10","volume":"30","author":"RS Kohler","year":"2010","unstructured":"Kohler RS, Schmitz D, Cornils H, Hemmings BA, Hergovich A. Differential NDR\/LATS interactions with the human MOB family reveal a negative role for human MOB2 in the regulation of human NDR kinases. Mol Cell Biol. 2010;30(18):4507\u201320. https:\/\/doi.org\/10.1128\/MCB.00150-10.","journal-title":"Mol Cell Biol"},{"key":"900_CR215","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4172\/2576-1471.1000125","volume":"1","author":"R Gundogdu","year":"2016","unstructured":"Gundogdu R, Hergovich A. The possible crosstalk of MOB2 with NDR1\/2 kinases in cell cycle and DNA damage signaling. J Cell Signal. 2016;1:125\u201333.","journal-title":"J Cell Signal."},{"issue":"21","key":"900_CR216","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1101\/gad.1602907","volume":"21","author":"B Zhao","year":"2007","unstructured":"Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747\u201361. https:\/\/doi.org\/10.1101\/gad.1602907.","journal-title":"Genes Dev"},{"issue":"5","key":"900_CR217","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.cell.2011.02.031","volume":"144","author":"K Schlegelmilch","year":"2011","unstructured":"Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, et al. Yap1 acts downstream of \u03b1-catenin to control epidermal proliferation. Cell. 2011;144(5):782\u201395. https:\/\/doi.org\/10.1016\/j.cell.2011.02.031.","journal-title":"Cell"},{"issue":"174","key":"900_CR218","doi-asserted-by":"publisher","first-page":"ra33","DOI":"10.1126\/scisignal.2001823","volume":"4","author":"MR Silvis","year":"2011","unstructured":"Silvis MR, Kreger BT, Lien WH, Klezovitch O, Rudakova GM, Camargo FD, et al. \u03b1-Catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal. 2011;4(174):ra33. https:\/\/doi.org\/10.1126\/scisignal.2001823.","journal-title":"Sci Signal."},{"issue":"3","key":"900_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.12.022","volume":"29","author":"D Levy","year":"2008","unstructured":"Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell. 2008;29(3): 350361. https:\/\/doi.org\/10.1016\/j.molcel.2007.12.022.","journal-title":"Mol Cell"},{"issue":"7","key":"900_CR220","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.cell.2012.11.026","volume":"151","author":"J Rosenbluh","year":"2012","unstructured":"Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, et al. \u03b2-catenin driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457\u201373. https:\/\/doi.org\/10.1016\/j.cell.2012.11.026.","journal-title":"Cell"},{"issue":"3","key":"900_CR221","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1083\/jcb.201501025","volume":"210","author":"NG Kim","year":"2015","unstructured":"Kim NG, Gumbiner BM. Adhesion to fibronectin regulates Hippo signaling via the FAK\u2013Src\u2013PI3K pathway. J Cell Biol. 2015;210(3):503\u201315. https:\/\/doi.org\/10.1083\/jcb.201501025.","journal-title":"J Cell Biol"},{"issue":"7451","key":"900_CR222","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu F-X, et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519(7451):57\u201362. https:\/\/doi.org\/10.1038\/nature14228.","journal-title":"Nature"},{"issue":"6","key":"900_CR223","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/cancers12061361","volume":"12","author":"PC Hsu","year":"2020","unstructured":"Hsu PC, Yang CT, Jablons DM, You L. The crosstalk between Src and Hippo\/YAP signaling pathways in non-small celllLung cancer (NSCLC). Cancers (Basel). 2020;12(6):1361\u201385. https:\/\/doi.org\/10.3390\/cancers12061361.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"900_CR224","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/molbev\/msr065","volume":"28","author":"D Hilman","year":"2011","unstructured":"Hilman D, Gat U. The evolutionary history of YAP and the hippo\/YAP pathway. Mol Biol Evol. 2011;28(8):2403\u201317. https:\/\/doi.org\/10.1093\/molbev\/msr065.","journal-title":"Mol Biol Evol"},{"issue":"7","key":"900_CR225","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","volume":"23","author":"W Hong","year":"2012","unstructured":"Hong W. Guan KL The YAP and TAZ transcription coactivators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23(7):785\u201393. https:\/\/doi.org\/10.1016\/j.semcdb.2012.05.004.","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"900_CR226","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.gene.2012.08.025","volume":"509","author":"CJ Gaffney","year":"2012","unstructured":"Gaffney CJ, Oka T, Mazack V, Hilman D, Gat U, Muramatsu T, et al. Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. Gene. 2012;509(2):215\u201322. https:\/\/doi.org\/10.1016\/j.gene.2012.08.025.","journal-title":"Gene"},{"key":"900_CR227","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.658481","volume":"9","author":"YS Cho","year":"2021","unstructured":"Cho YS, Jiang J. Hippo-independent regulation of Yki\/Yap\/Taz: a non-canonical view. Front Cell Dev Biol. 2021;9: 658481. https:\/\/doi.org\/10.3389\/fcell.2021.658481.","journal-title":"Front Cell Dev Biol."},{"issue":"5","key":"900_CR228","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/1541-7786.MCR-15-0020-T","volume":"13","author":"M Hartmann","year":"2015","unstructured":"Hartmann M, Parra LM, Ruschel A, B\u00f6hme S, Li Y, Morrison H, et al. Tumor suppressor NF2 blocks cellular migration by inhibiting ectodomain cleavage of CD44. Mol Cancer Res. 2015;13(5):879\u201390. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0020-T.","journal-title":"Mol Cancer Res"},{"key":"900_CR229","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fimmu.2015.00201","volume":"6","author":"S Misra","year":"2015","unstructured":"Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol. 2015;6:201. https:\/\/doi.org\/10.3389\/fimmu.2015.00201.","journal-title":"Front Immunol"},{"issue":"2","key":"900_CR230","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2006.12.025","volume":"252","author":"R Ohashi","year":"2007","unstructured":"Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett. 2007;252(2):225\u201334. https:\/\/doi.org\/10.1016\/j.canlet.2006.12.025.","journal-title":"Cancer Lett"},{"issue":"5","key":"900_CR231","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/1097-0142(19940301)73:5<1406::aid-cncr2820730515>3.0.co;2-i","volume":"73","author":"G Martensson","year":"1994","unstructured":"Martensson G, Thylen A, Lindquist U, Hjerpe A. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer. 1994;73(5):1406\u201310. https:\/\/doi.org\/10.1002\/1097-0142(19940301)73:5%3c1406::aid-cncr2820730515%3e3.0.co;2-i.","journal-title":"Cancer"},{"issue":"2","key":"900_CR232","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.resinv.2013.02.002","volume":"51","author":"N Fujimoto","year":"2013","unstructured":"Fujimoto N, Gemba K, Asano M, Fuchimoto Y, Wada S, Ono K, et al. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma. Respir Invest. 2013;51(2):92\u20137. https:\/\/doi.org\/10.1016\/j.resinv.2013.02.002.","journal-title":"Respir Invest"},{"issue":"1","key":"900_CR233","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12931-017-0546-5","volume":"18","author":"L Cortes-Dericks","year":"2017","unstructured":"Cortes-Dericks L, Schmid RA. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives. Respir Res. 2017;18(1):58\u201370. https:\/\/doi.org\/10.1186\/s12931-017-0546-5.","journal-title":"Respir Res"},{"issue":"16","key":"900_CR234","first-page":"4516","volume":"54","author":"T Asplund","year":"1994","unstructured":"Asplund T, Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 1994;54(16):4516\u201323.","journal-title":"Cancer Res"},{"key":"900_CR235","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.1038\/s41388-018-0405-y","volume":"37","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Shingyoku S, Miyake S, Tanaka A, Fudesaka S, Shimizu Y, et al. Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways. Oncogene. 2018;37:6357\u201367. https:\/\/doi.org\/10.1038\/s41388-018-0405-y.","journal-title":"Oncogene"},{"issue":"10","key":"900_CR236","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1016\/j.xphs.2019.06.012","volume":"108","author":"Y Sakurai","year":"2019","unstructured":"Sakurai Y, Kato A, Hida Y, Hamada J, Maishi N, Hida K, et al. Synergistic enhancement of cellular uptake with CD44-expressing malignant pleural mesothelioma by combining cationic liposome and hyaluronic acid-lipid conjugate. J Pharm Sci. 2019;108(10):3218\u201324. https:\/\/doi.org\/10.1016\/j.xphs.2019.06.012.","journal-title":"J Pharm Sci"},{"issue":"24","key":"900_CR237","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA. 1995;92(24):10854\u20138. https:\/\/doi.org\/10.1073\/pnas.92.24.10854.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"900_CR238","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227\u201331.","journal-title":"Cancer Res"},{"issue":"2","key":"900_CR239","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","volume":"64","author":"C Thurneysen","year":"2009","unstructured":"Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2\/merlin in human mesothelioma. Lung Cancer. 2009;64(2):140\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2008.08.014.","journal-title":"Lung Cancer"},{"issue":"7","key":"900_CR240","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/cr.2015.69","volume":"25","author":"Y Li","year":"2015","unstructured":"Li Y, Zhou H, Li F, Chan SW, Lin Z, Wei Z, et al. Angiomotin binding-induced activation of Merlin\/NF2 in the Hippo pathway. Cell Res. 2015;25(7):801\u201317. https:\/\/doi.org\/10.1038\/cr.2015.69.","journal-title":"Cell Res"},{"issue":"1","key":"900_CR241","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2006.06.017","volume":"54","author":"JR Fischer","year":"2006","unstructured":"Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 2006;54(1):109\u201316. https:\/\/doi.org\/10.1016\/j.lungcan.2006.06.017.","journal-title":"Lung Cancer"},{"issue":"3","key":"900_CR242","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.lungcan.2007.08.035","volume":"59","author":"A Destro","year":"2008","unstructured":"Destro A, Ceresoli GL, Baryshnikov E, Garassino I, Zucali PA, De Vincenzo F, et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient\u2019s follow-up. Lung Cancer. 2008;59(3):369\u201376. https:\/\/doi.org\/10.1016\/j.lungcan.2007.08.035.","journal-title":"Lung Cancer"},{"issue":"3","key":"900_CR243","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1349-7006.2011.02180.x","volume":"103","author":"M Fujii","year":"2012","unstructured":"Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci. 2012;103(3):510\u20134. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02180.x.","journal-title":"Cancer Sci"},{"issue":"1","key":"900_CR244","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12964-018-0276-4","volume":"6","author":"F Dubois","year":"2018","unstructured":"Dubois F, Jean-Jacques B, Roberge H, B\u00e9nard M, Galas L, Schapman D, et al. A role for RASSF1A in tunneling nanotube formation between cells through GEFH1\/Rab11 pathway control. Cell Commun Signal. 2018;6(1):66\u201386. https:\/\/doi.org\/10.1186\/s12964-018-0276-4.","journal-title":"Cell Commun Signal"},{"issue":"7","key":"900_CR245","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/cdd.2014.211","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang X, Gerdes HH. Transfer of mitochondria via tunneling nanotubes rescues apoptotic PC12 cells. Cell Death Differ. 2015;22(7):1181\u201391. https:\/\/doi.org\/10.1038\/cdd.2014.211.","journal-title":"Cell Death Differ"},{"key":"900_CR246","doi-asserted-by":"publisher","first-page":"6917841","DOI":"10.1155\/2017\/6917941","volume":"2017","author":"ML Vignais","year":"2017","unstructured":"Vignais ML, Caicedo A, Brondello JM, Jorgensen C. Cell connections by tunneling nanotubes: effects of mitochondrial trafficking on target cell metabolism, homeostasis, and response to therapy. Stem Cells Int. 2017;2017:6917841. https:\/\/doi.org\/10.1155\/2017\/6917941.","journal-title":"Stem Cells Int."},{"issue":"7","key":"900_CR247","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372. https:\/\/doi.org\/10.1038\/ng.855.","journal-title":"Nat Genet"},{"key":"900_CR248","doi-asserted-by":"publisher","first-page":"1310478","DOI":"10.1155\/2017\/1310478","volume":"2017","author":"E Pulford","year":"2017","unstructured":"Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S. Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis? Dis Markers. 2017;2017:1310478. https:\/\/doi.org\/10.1155\/2017\/1310478.","journal-title":"Dis Markers"},{"issue":"3","key":"900_CR249","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71(3):873\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2164.","journal-title":"Cancer Res"},{"issue":"5","key":"900_CR250","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","volume":"10","author":"A Miyanaga","year":"2015","unstructured":"Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T, et al. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing. J Thorac Oncol. 2015;10(5):844\u201351. https:\/\/doi.org\/10.1097\/JTO.0000000000000493.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"900_CR251","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41416-019-0379-8","volume":"120","author":"E Maille","year":"2019","unstructured":"Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, et al. MST1\/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial. Br J Cancer. 2019;120(4):387\u201397. https:\/\/doi.org\/10.1038\/s41416-019-0379-8.","journal-title":"Br J Cancer"},{"issue":"12","key":"900_CR252","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","volume":"23","author":"R Tranchant","year":"2017","unstructured":"Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, Koning L, et al. Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res. 2017;23(12):3191\u2013202. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1971.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"900_CR253","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.molonc.2016.06.005","volume":"10","author":"M Meerang","year":"2016","unstructured":"Meerang M, B\u00e9rard K, Friess M, Bitanihirwe BKY, Soltermann A, Vrugt B, et al. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Mol Oncol. 2016;10(8):1255\u201365. https:\/\/doi.org\/10.1016\/j.molonc.2016.06.005.","journal-title":"Mol Oncol"},{"issue":"6","key":"900_CR254","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","volume":"61","author":"Y Sekido","year":"2011","unstructured":"Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation: Merlin inactivation in mesothelioma. Pathol Int. 2011;61(6):331\u201344. https:\/\/doi.org\/10.1111\/j.1440-1827.2011.02666.x.","journal-title":"Pathol Int"},{"issue":"1","key":"900_CR255","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrd4161","volume":"13","author":"R Johnson","year":"2014","unstructured":"Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13(1):63\u201379. https:\/\/doi.org\/10.1038\/nrd4161.","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"900_CR256","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1038\/onc.2014.251","volume":"34","author":"W Mi","year":"2015","unstructured":"Mi W, Lin Q, Childress C, Sudol M, Robishaw J, Berlot CH, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene. 2015;34(24):3095\u2013106. https:\/\/doi.org\/10.1038\/onc.2014.251.","journal-title":"Oncogene"},{"issue":"14","key":"900_CR257","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1158\/0008-5472.CAN-19-3853","volume":"80","author":"KK Slemmons","year":"2020","unstructured":"Slemmons KK, Yeung C, Baumgart JT, Juarez JO, McCalla A, Helman LJ. Targeting Hippo-dependent and Hippo-independent YAP1 signaling for the treatment of childhood rhabdomyosarcoma. Cancer Res. 2020;80(14):3046\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3853.","journal-title":"Cancer Res"},{"issue":"2","key":"900_CR258","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3978\/j.issn.2218-6751.2014.02.03","volume":"3","author":"E Felley-Bosco","year":"2014","unstructured":"Felley-Bosco E, Stahel R. Hippo\/YAP pathway for targeted therapy. Transl Lung Cancer Res. 2014;3(2):75\u201383. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.02.03.","journal-title":"Transl Lung Cancer Res."},{"issue":"12","key":"900_CR259","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300\u20135. https:\/\/doi.org\/10.1101\/gad.192856.112.","journal-title":"Genes Dev"},{"issue":"11","key":"900_CR260","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/jcmm.13182","volume":"21","author":"WQ Zhang","year":"2017","unstructured":"Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL, et al. Targeting YAP in malignant pleural mesothelioma. J Cell Mol Med. 2017;21(11):2663\u201376. https:\/\/doi.org\/10.1111\/jcmm.13182.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"900_CR261","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13046-019-1352-3","volume":"38","author":"C Pulito","year":"2019","unstructured":"Pulito C, Korita E, Sacconi A, Valerio M, Casadei L, Lo Sardo F, et al. Dropwort-induced metabolic reprogramming restrains YAP\/TAZ\/TEAD oncogenic axis in mesothelioma. J Exp Clin Cancer Res. 2019;38(1):349\u201371. https:\/\/doi.org\/10.1186\/s13046-019-1352-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"900_CR262","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10989-020-10069-9","volume":"27","author":"D Wu","year":"2021","unstructured":"Wu D, Luo L, Yang Z, Chen Y, Quan Y, Min Z. Targeting human Hippo TEAD binding interface with YAP\/TAZ-derived, flexibility-reduced peptides in gastric cancer. Int J Peptide Res Ther. 2021;27(1):119\u201328. https:\/\/doi.org\/10.1007\/s10989-020-10069-9.","journal-title":"Int J Peptide Res Ther."},{"issue":"1","key":"900_CR263","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1038\/s41598-019-41404-w","volume":"9","author":"L Dominguez-Berrocal","year":"2019","unstructured":"Dominguez-Berrocal L, Cirri E, Zhang X, Marin GH, Lebel-Bina S, Rebollo A. New therapeutic approach for targeting Hippo signalling Pathway. Sci Rep. 2019;9(1):4771\u201382. https:\/\/doi.org\/10.1038\/s41598-019-41404-w.","journal-title":"Sci Rep"},{"issue":"4","key":"900_CR264","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","volume":"16","author":"G Sorrentino","year":"2014","unstructured":"Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357\u201366. https:\/\/doi.org\/10.1038\/ncb2936.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"900_CR265","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/jcp.25650","volume":"232","author":"L Sapio","year":"2017","unstructured":"Sapio L, Gallo M, Illiano M, Chiosi E, Naviglio D, Spina A, et al. The natural cAMP elevating compound forskolin in cancer therapy: is it time? J Cell Physiol. 2017;232(5):922\u20137. https:\/\/doi.org\/10.1002\/jcp.25650.","journal-title":"J Cell Physiol"},{"issue":"5","key":"900_CR266","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201900162","volume":"42","author":"BJ Thompson","year":"2020","unstructured":"Thompson BJ. YAP\/TAZ: drivers of tumor growth, metastasis, and resistance to therapy. BioEssays. 2020;42(5): e1900162. https:\/\/doi.org\/10.1002\/bies.201900162.","journal-title":"BioEssays"},{"key":"900_CR267","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2021.03.006","volume":"507","author":"S Mohajan","year":"2021","unstructured":"Mohajan S, Jaiswal PK, Vatanmakarian M, Yousefi H, Sankaralingam S, Alahar SK, et al. Hippo pathway: regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 2021;507:112\u201323. https:\/\/doi.org\/10.1016\/j.canlet.2021.03.006.","journal-title":"Cancer Lett"},{"issue":"2","key":"900_CR268","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/cancers13020318","volume":"13","author":"R Zeng","year":"2021","unstructured":"Zeng R, Dong J. The Hippo signaling pathway in drug resistance in cancer. Cancers (Basel). 2021;13(2):318. https:\/\/doi.org\/10.3390\/cancers13020318.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"900_CR269","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4161\/cbt.24345","volume":"14","author":"N Bai","year":"2013","unstructured":"Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J, et al. Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther. 2013;14(6):511\u201320. https:\/\/doi.org\/10.4161\/cbt.24345.","journal-title":"Cancer Biol Ther"},{"issue":"41","key":"900_CR270","doi-asserted-by":"publisher","first-page":"27534","DOI":"10.1074\/jbc.M804380200","volume":"283","author":"T Oka","year":"2008","unstructured":"Oka T, Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem. 2008;283(41):27534\u201346. https:\/\/doi.org\/10.1074\/jbc.M804380200.","journal-title":"J Biol Chem"},{"issue":"1","key":"900_CR271","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/onc.2011.216","volume":"31","author":"T Oka","year":"2012","unstructured":"Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene. 2012;31(1):128\u201334. https:\/\/doi.org\/10.1038\/onc.2011.216.","journal-title":"Oncogene"},{"issue":"1","key":"900_CR272","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/jid.2013.319","volume":"134","author":"F Nallet-Staub","year":"2014","unstructured":"Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, et al. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2014;134(1):123\u201332. https:\/\/doi.org\/10.1038\/jid.2013.319.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"900_CR273","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"Piccolo S, Dupont S, Cordenonsi M. The biology of YAP\/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287\u2013312. https:\/\/doi.org\/10.1152\/physrev.00005.2014.","journal-title":"Physiol Rev"},{"key":"900_CR274","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/abbs\/gmu110","volume":"47","author":"C Zhu","year":"2015","unstructured":"Zhu C, Li L, Zhao B. The regulation and function of YAP transcription co-activator. Acta Biochim Biophys Sin. 2015;47:16\u201328.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"2","key":"900_CR275","doi-asserted-by":"publisher","first-page":"188","DOI":"10.15252\/embr.201540488","volume":"17","author":"S Di Agostino","year":"2016","unstructured":"Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, et al. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016;17(2):188\u2013201. https:\/\/doi.org\/10.15252\/embr.201540488.","journal-title":"EMBO Rep"},{"issue":"1","key":"900_CR276","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4161\/cc.8.1.7259","volume":"8","author":"E Bertini","year":"2009","unstructured":"Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: At the crossroad between transformation and tumor suppression. Cell Cycle. 2009;8(1):49\u201357. https:\/\/doi.org\/10.4161\/cc.8.1.7259.","journal-title":"Cell Cycle"},{"issue":"5","key":"900_CR277","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","volume":"61","author":"A Perra","year":"2014","unstructured":"Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088\u201396. https:\/\/doi.org\/10.1016\/j.jhep.2014.06.033.","journal-title":"J Hepatol"},{"issue":"1","key":"900_CR278","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-013-9463-3","volume":"33","author":"H Wang","year":"2014","unstructured":"Wang H, Du YC, Zhou X, Liu H. Tang SC (2014) The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy. Cancer Metastasis Rev. 2014;33(1):173\u201381. https:\/\/doi.org\/10.1007\/s10555-013-9463-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"900_CR279","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cncr.22552","volume":"109","author":"AY Lee","year":"2007","unstructured":"Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109(8):1454\u201361. https:\/\/doi.org\/10.1002\/cncr.22552.","journal-title":"Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00900-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00900-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00900-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T11:31:02Z","timestamp":1659439862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00900-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":279,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00900-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"5 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fat\u00e9m\u00e9h Dubois, C\u00e9line Bazille, J\u00e9r\u00f4me Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, G\u00e9rard Zalcman, and Gu\u00e9na\u00eblle Levallet have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FD, EM, and GL wrote the original draft of this article, which was then proofread, corrected, and validated by FD, CB, JL, EM, SB, JM, EB, GZ, and GL.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}